PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35131711-8 2022 We also show that the combination of doxorubicin and L-DOPA drugs impedes the alpha-synuclein aggregation. Levodopa 53-59 synuclein alpha Homo sapiens 78-93 1899328-3 1991 We have investigated the oxidation chemistry of a low molecular weight peptidyl DOPA analog, N-acetylDOPA ethyl ester (NAcDEE), and have shown that a major product of oxidation is an unsaturated DOPA derivative, N-acetyl-alpha,beta-dehydroDOPA ethyl ester (NAc delta DEE) (see companion paper, Rzepecki et al., Arch. Levodopa 80-84 synuclein alpha Homo sapiens 119-122 1899328-3 1991 We have investigated the oxidation chemistry of a low molecular weight peptidyl DOPA analog, N-acetylDOPA ethyl ester (NAcDEE), and have shown that a major product of oxidation is an unsaturated DOPA derivative, N-acetyl-alpha,beta-dehydroDOPA ethyl ester (NAc delta DEE) (see companion paper, Rzepecki et al., Arch. Levodopa 101-105 synuclein alpha Homo sapiens 119-122 34297092-9 2021 In an additional set of experiments, we were able to rescue alpha-synuclein-induced alterations of motor function, striatal synaptic plasticity, and increased spontaneous excitatory synaptic currents by a sub-chronic treatment with L-Dopa, a precursor of dopamine widely used in the therapy of Parkinson"s disease, clearly demonstrating that a dysfunctional dopamine system plays a critical role in the early phases of the disease. Levodopa 232-238 synuclein alpha Homo sapiens 60-75 32921640-7 2020 In this study, we first showed that a low concentration of L-DOPA (100 muM) rescues locomotion defects (i.e., speed, angular velocity, pause time) in Drosophila larvae expressing human mutant alpha-synuclein (A53T). Levodopa 59-65 synuclein alpha Homo sapiens 192-207 35172843-9 2022 RESULTS: We show in primary human microglia that dopamine, L-DOPA, and high extracellular K+, but not norepinephrine and epinephrine, block canonical, non-canonical, and alpha-syn-mediated NLRP3 inflammasome-driven IL-1beta secretion. Levodopa 59-65 synuclein alpha Homo sapiens 170-179 33275784-0 2021 L-DOPA regulates alpha-synuclein accumulation in experimental parkinsonism. Levodopa 0-6 synuclein alpha Homo sapiens 17-32 33275784-9 2021 The MPTP-induced increase in alpha-synuclein levels was abolished in animals having received L-DOPA in all the brain regions, except in the substantia nigra. Levodopa 93-99 synuclein alpha Homo sapiens 29-44 32313102-5 2020 Additional analysis revealed significant association of alpha-syn-specific T cell responses with age and lower levodopa equivalent dose. Levodopa 111-119 synuclein alpha Homo sapiens 56-65 32541823-6 2020 alpha-synuclein overexpression led to an early loss of DACs associated with a decrease of light-adapted ERG responses and visual acuity that could be rescued by systemic injections of L-DOPA. Levodopa 184-190 synuclein alpha Homo sapiens 0-15 31136763-1 2019 Rat models based on viral vector-mediated overexpression of alpha-synuclein are regarded as highly valuable models that closely mimic cardinal features of human Parkinson"s disease (PD) such as L-DOPA-dependent motor impairment, dopaminergic neurodegeneration and alpha-synuclein inclusions. Levodopa 194-200 synuclein alpha Homo sapiens 60-75 31405930-9 2019 We previously showed that abrogating native alpha-synuclein (alphaS) tetramers produces a close PD model, including dopaminergic and cortical fiber loss and a progressive motor disorder responsive to l-DOPA. Levodopa 200-206 synuclein alpha Homo sapiens 44-59 30357936-6 2018 SNCA mutation carriers often have additional psychiatric symptoms, and although not exclusive to only LRRK2 or VPS35 mutation carriers, LRRK2 mutation carriers have a typical form of PD, and, lastly, VPS35 mutation carriers have good response to l-dopa. Levodopa 246-252 synuclein alpha Homo sapiens 0-4 29907754-6 2018 The obtained results concluded that CeO2 NP fit best in the active site of alpha-synuclein with good contacts and interaction, and potentially inhibited the PD against L-DOPA drug selected as positive control in the designed PD biochemical pathway. Levodopa 168-174 synuclein alpha Homo sapiens 75-90 30026036-8 2018 We further hypothesize that the peculiar pattern of alpha-synuclein pathology may contribute to differences in the clinical phenotype, with a greater proportion of neuronal inclusions in the putamen being associated to a milder, "PD-like" phenotype with sustained levodopa response and slower disease progression. Levodopa 264-272 synuclein alpha Homo sapiens 52-67 21917769-1 2011 BACKGROUND: Several in vitro studies have suggested levodopa (L-dopa) to be toxic to dopaminergic neurons and that it can modulate the aggregation process of alpha-synuclein. Levodopa 52-60 synuclein alpha Homo sapiens 158-173 29217686-4 2018 Interestingly, NSC loss in alpha-SYN-deficient mice can be prevented by viral delivery of human alpha-SYN into their sustantia nigra or by treatment with l-DOPA, suggesting that alpha-SYN regulates dopamine availability to NSCs. Levodopa 154-160 synuclein alpha Homo sapiens 27-36 28687316-0 2017 Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under alpha-synuclein-induced toxicity. Levodopa 0-8 synuclein alpha Homo sapiens 137-152 28687316-0 2017 Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under alpha-synuclein-induced toxicity. Levodopa 10-16 synuclein alpha Homo sapiens 137-152 28687316-5 2017 In the present study, we investigated the effect of L-DOPA on SH-SY5Y neuronal cells under alpha-syn-induced toxicity. Levodopa 52-58 synuclein alpha Homo sapiens 91-100 28687316-8 2017 In conclusion, we suggest that L-DOPA may attenuate the neuropathology of PD by regulating signaling related to DRD2 in neuronal cells under alpha-syn-induced toxicity. Levodopa 31-37 synuclein alpha Homo sapiens 141-150 26306801-4 2015 The H50Q SNCA mutation case had a clinical picture that mimicked late-onset idiopathic PD with a good and sustained levodopa response. Levodopa 116-124 synuclein alpha Homo sapiens 9-13 26306801-5 2015 The SNCA duplication case presented with a clinical phenotype of frontotemporal dementia with marked behavioural changes, pyramidal signs, postural hypotension and transiently levodopa responsive parkinsonism. Levodopa 176-184 synuclein alpha Homo sapiens 4-8 29233065-5 2018 The mechanisms of L-DOPA toxicity involve oxidative stress, L-DOPA oxidation to quinone, mitochondrial dysfunction, and alpha-synuclein. Levodopa 18-24 synuclein alpha Homo sapiens 120-135 26606044-0 2016 Levodopa-Induced Motor and Dopamine Receptor Changes in Caenorhabditis elegans Overexpressing Human Alpha-Synuclein. Levodopa 0-8 synuclein alpha Homo sapiens 100-115 26606044-5 2016 We aimed to study levodopa-induced changes in a Parkinson"s disease model of C. elegans expressing human alpha-synuclein. Levodopa 18-26 synuclein alpha Homo sapiens 105-120 26606044-6 2016 METHODS: We exposed the alpha-synuclein C. elegans to levodopa in continuous and alternating fashions. Levodopa 54-62 synuclein alpha Homo sapiens 24-39 26606044-9 2016 RESULTS: Chronic exposure to levodopa led to hyperactivity of the alpha-synuclein C. elegans without meaningful increase in motor activity. Levodopa 29-37 synuclein alpha Homo sapiens 66-81 26606044-12 2016 CONCLUSIONS: This is the first report of changes in motor and dopamine receptors induced by levodopa in C. elegans overexpressing human alpha-synuclein. Levodopa 92-100 synuclein alpha Homo sapiens 136-151 26173746-0 2015 L-dopa increases alpha-synuclein DNA methylation in Parkinson"s disease patients in vivo and in vitro. Levodopa 0-6 synuclein alpha Homo sapiens 17-32 26173746-5 2015 alpha-Synuclein methylation was increased in sporadic PD patients with higher l-dopa dosage, and L-dopa specifically induced methylation of alpha-synuclein intron 1 in cultured mononuclear cells. Levodopa 78-84 synuclein alpha Homo sapiens 0-15 26173746-8 2015 The hypomethylation of alpha-synuclein in sporadic PD patients" blood already observed in previous studies was probably underestimated because of effect of L-dopa, which was not known previously. Levodopa 156-162 synuclein alpha Homo sapiens 23-38 21917769-1 2011 BACKGROUND: Several in vitro studies have suggested levodopa (L-dopa) to be toxic to dopaminergic neurons and that it can modulate the aggregation process of alpha-synuclein. Levodopa 62-68 synuclein alpha Homo sapiens 158-173 19409267-5 2009 DA(cyt) was not altered by alpha-synuclein deletion, although dopaminergic neurons lacking alpha-synuclein were resistant to L-DOPA-induced cell death. Levodopa 125-131 synuclein alpha Homo sapiens 91-106 10599788-2 1999 BACKGROUND: Mutations of alpha-synuclein have been associated recently with dominantly inherited, levodopa-responsive parkinsonism. Levodopa 98-106 synuclein alpha Homo sapiens 25-40 15109582-3 2004 alpha-Synuclein positive, neuritic pathology, in the putamen of DLB and Parkinson"s disease dementia (PDD), may contribute to postural-instability gait difficulty, parkinsonism, diminished levodopa responsiveness and increased neuroleptic sensitivity. Levodopa 189-197 synuclein alpha Homo sapiens 0-15 10482268-2 1999 We report that the phenotype of a kindred (Family H) with autosomal dominant, levodopa-responsive parkinsonism maps to chromosomal region 4q21-23 and that affected members of this kindred harbor a previously reported mutation (G209A) in exon 4 of the alpha-synuclein gene. Levodopa 78-86 synuclein alpha Homo sapiens 251-266